Affimed N.V., a clinical-stage biopharmaceutical company, is dedicated to discovering and developing innovative cancer immunotherapies across the United States, Germany, and Europe. With an extensive pipeline of experimental products, the company's lead candidates, including AFM13 and AFM24, have completed Phase 2 clinical trials for CD30-positive lymphoma and advanced cancers, respectively, while AFM28 is currently in pre-clinical development for acute myeloid leukemia. The company also collaborates with Artiva Biotherapeutics and Roivant Sciences Ltd. to develop novel ICE molecules and solid tumor treatments. Additionally, Affimed N.V. has a research collaboration and license agreement with Genentech to advance its NK cell engager-based immunotherapeutics for cancer treatment. The company, once known as Affimed Therapeutics B.V., was established in 2000 and is headquartered in Heidelberg, Germany.
Affimed's ticker is AFMD
The company's shares trade on the NASDAQ stock exchange
They are based in Heidelberg, Germany
There are 51-200 employees working at Affimed
It is affimed.com
Affimed is in the Healthcare sector
Affimed is in the Biotechnology industry
The following five companies are Affimed's industry peers: